Whipplewood Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.1K Sell
167
-1,100
-87% -$64.1K 0.01% 485
2025
Q4
$68.3K Hold
1,267
0.04% 179
2025
Q3
$57.1K Sell
1,267
-224
-15% -$10.5K 0.04% 186
2025
Q2
$69K Sell
1,491
-58
-4% -$2.85K 0.04% 278
2025
Q1
$92.3K Buy
1,549
+106
+7% +$6.18K 0.05% 230
2024
Q4
$81.6K Buy
+1,443
New +$80.6K 0.05% 249

Other funds holding BMY

Whipplewood Advisors's BMY Position: Q1 2026 in Review

Whipplewood Advisors reduced its Bristol-Myers Squibb (BMY) stake by 87% in Q1 2026, selling an estimated $64.1K and leaving 167 shares worth $10.1K. The position accounts for 0.01% of the portfolio, ranked #485.

Whipplewood Advisors first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $92.3K in Q1 2025. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Whipplewood Advisors held 167 shares of Bristol-Myers Squibb worth $10.1K as of Q1 2026.
  • Whipplewood Advisors sold 1,100 Bristol-Myers Squibb shares in Q1 2026, an estimated $64.1K.
  • Bristol-Myers Squibb made up 0.01% of Whipplewood Advisors's portfolio in Q1 2026, its #485 holding.
  • Whipplewood Advisors first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • Whipplewood Advisors's Bristol-Myers Squibb position peaked at $92.3K in Q1 2025.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Whipplewood Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.